Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fracture: a double-blind placebo-controlled pilot study in 20 patients.

Plain-language guide to PMID 15370581 (2004): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.

Key Facts

PMID: 15370581
Journal: Acta orthopaedica Scandinavica
Year: 2004
Study type: Randomized Controlled Trial
Authors: Hedström M et al. (7 authors)
DOI: 10.1080/00016470410001141-1

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

A catabolic state develops after a hip fracture, with loss of muscle and bone tissue.

Who Took Part

The study group was 20 patients.

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

The patients were followed for another 2 months after termination of GH treatment.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

The subject headings attached to it are Body Mass Index, Bone Density, Growth Hormone, Hip Fractures, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor I and Pilot Projects.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Acta orthopaedica Scandinavica), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.